这是一篇来自已证抗体库的有关人类 Vegfr-3的综述，是根据32篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合Vegfr-3 抗体。
Vegfr-3 同义词: FLT-4; FLT41; LMPH1A; LMPHM1; PCL; VEGFR-3; VEGFR3

安迪生物R&D
domestic goat 多克隆
  • 免疫细胞化学; 小鼠; 1:100; 图 s4a
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫细胞化学在小鼠样本上浓度为1:100 (图 s4a). Nat Commun (2021) ncbi
domestic goat 多克隆
  • 免疫组化; 小鼠; 1:50; 图 4a
  • 免疫印迹; 小鼠; 1:5000; 图 7a
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化在小鼠样本上浓度为1:50 (图 4a) 和 被用于免疫印迹在小鼠样本上浓度为1:5000 (图 7a). iScience (2021) ncbi
domestic goat 多克隆
  • 免疫组化; 小鼠
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化在小鼠样本上. Mucosal Immunol (2021) ncbi
domestic goat 多克隆
  • 免疫组化; 小鼠; 图 1
安迪生物R&D Vegfr-3抗体（R和D, AF743)被用于被用于免疫组化在小鼠样本上 (图 1). elife (2020) ncbi
domestic goat 多克隆
  • 免疫组化-冰冻切片; 小鼠; 1:200; 图 8b
安迪生物R&D Vegfr-3抗体（R&D, AF743)被用于被用于免疫组化-冰冻切片在小鼠样本上浓度为1:200 (图 8b). elife (2020) ncbi
domestic goat 多克隆
  • 免疫组化; 小鼠; 1:100-1:200; 图 1d
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化在小鼠样本上浓度为1:100-1:200 (图 1d). Acta Neuropathol (2020) ncbi
domestic goat 多克隆
  • 免疫组化-石蜡切片; 小鼠; 图 2a
安迪生物R&D Vegfr-3抗体（R&D, AF743)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 2a). EMBO J (2019) ncbi
domestic goat 多克隆
  • 免疫组化-冰冻切片; 小鼠; 图 s1a
  • 免疫组化; 小鼠
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 s1a) 和 被用于免疫组化在小鼠样本上. Proc Natl Acad Sci U S A (2018) ncbi
domestic goat 多克隆
  • 免疫组化-冰冻切片; 小鼠; 图 s3c
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 s3c). J Clin Invest (2017) ncbi
domestic goat 多克隆
  • 免疫组化-石蜡切片; 小鼠; 图 s1c
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化-石蜡切片在小鼠样本上 (图 s1c). Nature (2017) ncbi
domestic goat 多克隆
  • 免疫组化; 小鼠; 图 2j
安迪生物R&D Vegfr-3抗体（R&D, AF743)被用于被用于免疫组化在小鼠样本上 (图 2j). Nature (2017) ncbi
domestic goat 多克隆
  • 免疫组化-冰冻切片; 小鼠; 图 s5b
  • 免疫印迹; 小鼠; 图 3i
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 s5b) 和 被用于免疫印迹在小鼠样本上 (图 3i). J Clin Invest (2017) ncbi
domestic goat 多克隆
  • 免疫印迹; 人类; 图 4a
安迪生物R&D Vegfr-3抗体（R&D Systems, AF349)被用于被用于免疫印迹在人类样本上 (图 4a). J Clin Invest (2017) ncbi
domestic goat 多克隆
  • 免疫组化; 小鼠; 1:100; 图 5b
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化在小鼠样本上浓度为1:100 (图 5b). Development (2016) ncbi
domestic goat 多克隆
  • 流式细胞仪; 小鼠; 图 1
安迪生物R&D Vegfr-3抗体（R&D systems, AF743)被用于被用于流式细胞仪在小鼠样本上 (图 1). Arthritis Res Ther (2016) ncbi
domestic goat 多克隆
  • 免疫组化-冰冻切片; 小鼠; 图 1
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 1). Dev Biol (2016) ncbi
domestic goat 多克隆
  • 抑制或激活实验; 小鼠; 1:200; 图 2
  • 免疫细胞化学; 小鼠; 1:200; 图 6
安迪生物R&D Vegfr-3抗体（AngioBio, AF743)被用于被用于抑制或激活实验在小鼠样本上浓度为1:200 (图 2) 和 被用于免疫细胞化学在小鼠样本上浓度为1:200 (图 6). Nat Commun (2016) ncbi
domestic goat 多克隆
安迪生物R&D Vegfr-3抗体（R and D Systems, AF743)被用于. PLoS ONE (2015) ncbi
小鼠 单克隆（54733）
  • 流式细胞仪; 人类; 表 1
安迪生物R&D Vegfr-3抗体（R&D, FAB3492)被用于被用于流式细胞仪在人类样本上 (表 1). PLoS ONE (2015) ncbi
domestic goat 多克隆
  • 免疫组化-石蜡切片; 小鼠; 1:50; 图 3
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化-石蜡切片在小鼠样本上浓度为1:50 (图 3). Angiogenesis (2016) ncbi
小鼠 单克隆（54733）
  • 流式细胞仪; 人类; 1:50; 图 s5
安迪生物R&D Vegfr-3抗体（R&D, FAB3492P)被用于被用于流式细胞仪在人类样本上浓度为1:50 (图 s5). Nat Biotechnol (2015) ncbi
domestic goat 多克隆
  • 免疫组化-冰冻切片; 小鼠; 图 1h
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 1h). J Am Soc Nephrol (2016) ncbi
domestic goat 多克隆
安迪生物R&D Vegfr-3抗体（R&D Systems, AF743)被用于. Nature (2015) ncbi
BioLegend
小鼠 单克隆（9D9F9）
BioLegend Vegfr-3抗体（Biolegend, 356201)被用于. Nat Commun (2016) ncbi
小鼠 单克隆（9D9F9）
  • 流式细胞仪; 小鼠; 1:100; 图 6
  • 免疫细胞化学; 小鼠; 1:100; 图 6
BioLegend Vegfr-3抗体（BioLegend, 9D9F9)被用于被用于流式细胞仪在小鼠样本上浓度为1:100 (图 6) 和 被用于免疫细胞化学在小鼠样本上浓度为1:100 (图 6). Nat Commun (2016) ncbi
小鼠 单克隆（9D9F9）
  • 流式细胞仪; 人类; 图 1b
BioLegend Vegfr-3抗体（Biolegend, 9D9F9)被用于被用于流式细胞仪在人类样本上 (图 1b). Am J Physiol Lung Cell Mol Physiol (2016) ncbi
小鼠 单克隆（9D9F9）
  • 免疫组化-石蜡切片; 人类; 图 5k
BioLegend Vegfr-3抗体（BioLegend Inc., 356202)被用于被用于免疫组化-石蜡切片在人类样本上 (图 5k). J Pathol (2016) ncbi
小鼠 单克隆（9D9F9）
  • 流式细胞仪; 人类; 1:50; 图 2
BioLegend Vegfr-3抗体（BioLegend, 356204)被用于被用于流式细胞仪在人类样本上浓度为1:50 (图 2). J Vis Exp (2015) ncbi
圣克鲁斯生物技术
小鼠 单克隆（G-3）
  • 免疫印迹; 小鼠; 1:200; 图 2
圣克鲁斯生物技术 Vegfr-3抗体（Santa Cruz, sc-365748)被用于被用于免疫印迹在小鼠样本上浓度为1:200 (图 2). Arch Med Sci (2016) ncbi
小鼠 单克隆（D-6）
  • 免疫组化; 人类; 1:50
圣克鲁斯生物技术 Vegfr-3抗体（Santa Cruz, Sc-28297)被用于被用于免疫组化在人类样本上浓度为1:50. J Transl Med (2014) ncbi
艾博抗（上海）贸易有限公司
domestic rabbit 多克隆
  • 免疫组化-石蜡切片; 人类; 1:100; 图 2
艾博抗（上海）贸易有限公司 Vegfr-3抗体（Abcam, ab27278)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 2). BMC Cancer (2020) ncbi
domestic rabbit 多克隆
  • 免疫组化-冰冻切片; 小鼠; 图 6a
艾博抗（上海）贸易有限公司 Vegfr-3抗体（Abcam, ab27278)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 6a). BMC Cancer (2016) ncbi
赛默飞世尔
domestic rabbit 多克隆
  • 免疫组化; 人类; 图 2c
赛默飞世尔 Vegfr-3抗体（Thermo Scientific, PA1-37712)被用于被用于免疫组化在人类样本上 (图 2c). Ann Oncol (2017) ncbi
赛信通（上海）生物试剂有限公司
domestic rabbit 单克隆（C28G5）
  • 免疫印迹; 小鼠; 1:1000; 图 s10c
赛信通（上海）生物试剂有限公司 Vegfr-3抗体（Cell Signaling, 2638)被用于被用于免疫印迹在小鼠样本上浓度为1:1000 (图 s10c). Development (2016) ncbi
文章列表
  1. Zhang D, Huang J, Sun X, Chen H, Huang S, Yang J, et al. Targeting local lymphatics to ameliorate heterotopic ossification via FGFR3-BMPR1a pathway. Nat Commun. 2021;12:4391 pubmed 出版商
  2. Maruyama K, Naemura K, Arima Y, Uchijima Y, Nagao H, Yoshihara K, et al. Semaphorin3E-PlexinD1 signaling in coronary artery and lymphatic vessel development with clinical implications in myocardial recovery. iScience. 2021;24:102305 pubmed 出版商
  3. Maisel K, Hrusch C, Medellin J, Potin L, Chapel D, Nurmi H, et al. Pro-lymphangiogenic VEGFR-3 signaling modulates memory T cell responses in allergic airway inflammation. Mucosal Immunol. 2021;14:144-151 pubmed 出版商
  4. Norden P, Sabine A, Wang Y, Demir C, Liu T, Petrova T, et al. Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation. elife. 2020;9: pubmed 出版商
  5. Padthaisong S, Thanee M, Namwat N, Phetcharaburanin J, Klanrit P, Khuntikeo N, et al. A panel of protein kinase high expression is associated with postoperative recurrence in cholangiocarcinoma. BMC Cancer. 2020;20:154 pubmed 出版商
  6. Engelbrecht E, Lévesque M, He L, Vanlandewijck M, Nitzsche A, Niazi H, et al. Sphingosine 1-phosphate-regulated transcriptomes in heterogenous arterial and lymphatic endothelium of the aorta. elife. 2020;9: pubmed 出版商
  7. Shibata Germanos S, Goodman J, Grieg A, Trivedi C, Benson B, Foti S, et al. Structural and functional conservation of non-lumenized lymphatic endothelial cells in the mammalian leptomeninges. Acta Neuropathol. 2020;139:383-401 pubmed 出版商
  8. Urner S, Planas Paz L, Hilger L, Henning C, Branopolski A, Kelly Goss M, et al. Identification of ILK as a critical regulator of VEGFR3 signalling and lymphatic vascular growth. EMBO J. 2019;38: pubmed 出版商
  9. Souma T, Thomson B, Heinen S, Carota I, Yamaguchi S, Onay T, et al. Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP. Proc Natl Acad Sci U S A. 2018;115:1298-1303 pubmed 出版商
  10. Kim J, Park D, Bae H, Park D, Kim D, Lee C, et al. Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma. J Clin Invest. 2017;127:3877-3896 pubmed 出版商
  11. Olmeda D, Cerezo Wallis D, Riveiro Falkenbach E, Pennacchi P, Contreras Alcalde M, Ibarz N, et al. Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine. Nature. 2017;546:676-680 pubmed 出版商
  12. Wong B, Wang X, Zecchin A, Thienpont B, Cornelissen I, Kalucka J, et al. The role of fatty acid ?-oxidation in lymphangiogenesis. Nature. 2017;542:49-54 pubmed 出版商
  13. Lee S, Rho S, Park H, Park J, Kim J, Lee I, et al. Carbohydrate-binding protein CLEC14A regulates VEGFR-2- and VEGFR-3-dependent signals during angiogenesis and lymphangiogenesis. J Clin Invest. 2017;127:457-471 pubmed 出版商
  14. Wang Y, Baeyens N, Corti F, Tanaka K, Fang J, Zhang J, et al. Syndecan 4 controls lymphatic vasculature remodeling during mouse embryonic development. Development. 2016;143:4441-4451 pubmed
  15. Agulnik M, Costa R, Milhem M, Rademaker A, Prunder B, Daniels D, et al. A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas. Ann Oncol. 2017;28:121-127 pubmed 出版商
  16. Yue T, Zheng X, Dou Y, Zheng X, Sun R, Tian Z, et al. Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy. BMC Cancer. 2016;16:665 pubmed 出版商
  17. Zhu Y, Wu Y, Liang Y, Tan W, Liu Z, Xiao J. Regulation of expression level of fms-like tyrosine kinase-4 is related to osteoclast differentiation. Arch Med Sci. 2016;12:502-6 pubmed 出版商
  18. Karlas A, Berrè S, Couderc T, Varjak M, Braun P, Meyer M, et al. A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs. Nat Commun. 2016;7:11320 pubmed 出版商
  19. Chen W, Cao Z, Sugaya S, Lopez M, Sendra V, Laver N, et al. Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3. Nat Commun. 2016;7:11302 pubmed 出版商
  20. Ando K, Fujino N, Mitani K, Ota C, Okada Y, Kondo T, et al. Isolation of individual cellular components from lung tissues of patients with lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol. 2016;310:L899-908 pubmed 出版商
  21. Liang Q, Ju Y, Chen Y, Wang W, Li J, Zhang L, et al. Lymphatic endothelial cells efferent to inflamed joints produce iNOS and inhibit lymphatic vessel contraction and drainage in TNF-induced arthritis in mice. Arthritis Res Ther. 2016;18:62 pubmed 出版商
  22. Munger S, Geng X, Srinivasan R, Witte M, Paul D, Simon A. Segregated Foxc2, NFATc1 and Connexin expression at normal developing venous valves, and Connexin-specific differences in the valve phenotypes of Cx37, Cx43, and Cx47 knockout mice. Dev Biol. 2016;412:173-90 pubmed 出版商
  23. Wong H, Jin G, Cao R, Zhang S, Cao Y, Zhou Z. MT1-MMP sheds LYVE-1 on lymphatic endothelial cells and suppresses VEGF-C production to inhibit lymphangiogenesis. Nat Commun. 2016;7:10824 pubmed 出版商
  24. Sato T, Paquet Fifield S, Harris N, Roufail S, Turner D, Yuan Y, et al. VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. J Pathol. 2016;239:152-61 pubmed 出版商
  25. Zhou Y, Williams J, Smallwood P, Nathans J. Sox7, Sox17, and Sox18 Cooperatively Regulate Vascular Development in the Mouse Retina. PLoS ONE. 2015;10:e0143650 pubmed 出版商
  26. Zomerman W, Plasschaert S, Diks S, Lourens H, Meeuwsen de Boer T, Hoving E, et al. Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines. PLoS ONE. 2015;10:e0141381 pubmed 出版商
  27. Janssen L, Dupont L, Bekhouche M, Noel A, Leduc C, Voz M, et al. ADAMTS3 activity is mandatory for embryonic lymphangiogenesis and regulates placental angiogenesis. Angiogenesis. 2016;19:53-65 pubmed 出版商
  28. Birket M, Ribeiro M, Verkerk A, Ward D, Leitoguinho A, Den Hartogh S, et al. Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells. Nat Biotechnol. 2015;33:970-9 pubmed 出版商
  29. Huang J, Woolf A, Kolatsi Joannou M, Baluk P, Sandford R, Peters D, et al. Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases. J Am Soc Nephrol. 2016;27:69-77 pubmed 出版商
  30. Louveau A, Smirnov I, Keyes T, Eccles J, Rouhani S, Peske J, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337-41 pubmed 出版商
  31. Lokmic Z, Ng E, Burton M, Stanley E, Penington A, Elefanty A. Isolation of human lymphatic endothelial cells by multi-parameter fluorescence-activated cell sorting. J Vis Exp. 2015;:e52691 pubmed 出版商
  32. Zakaria N, Possemiers T, Dhubhghaill S, Leysen I, Rozema J, Koppen C, et al. Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation. J Transl Med. 2014;12:58 pubmed 出版商